JP Morgan Put 120 PSX 17.01.2025/ DE000JB2N511 /
6/27/2024 8:56:31 AM | Chg.+0.020 | Bid12:13:24 PM | Ask12:13:24 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.750EUR | +2.74% | 0.740 Bid Size: 3,000 |
0.820 Ask Size: 3,000 |
Phillips 66 | 120.00 USD | 1/17/2025 | Put |
GlobeNewswire
12:00 PM
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Inte...
GlobeNewswire
6/26
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulat...
GlobeNewswire
6/25
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technolog...
GlobeNewswire
6/20
The International Food Information Council (IFIC) Releases Annual Food & Health Survey Revealing Ris...
GlobeNewswire
6/17
Phillips Edison & Company Inc. Invites You to Join Its Second Quarter 2024 Earnings Conference Call
GlobeNewswire
6/17
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
6/12
Greystone Closes $22.9 Million in Total Debt Placement and Preferred Equity Financing for Fort Worth...
GlobeNewswire
6/5
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
5/22
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
GlobeNewswire
5/20
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease We...
GlobeNewswire
5/16
Optimal Daily Dairy Consumption Remains Elusive Despite Well-Established Health Benefits
GlobeNewswire
5/16
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)